logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Smart Inhalers market, By Product (MDI, DPI, Nebulizers) By Indication (Asthma, COPD) By End Use (Hospital pharmacies, Retail Pharmacies, Online Pharmacies and Others) opportunities and forecast 2020-2027

  • DLR2186
  • 19 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Smart inhalers are the inhalers that can be connected to the multiple devices to take patients’ health updates especially for the people suffering from respiratory diseases such as asthma and COPD. Advance technological products requirements in healthcare is one of the major drivers of this market. Large number of people suffering from the diseases worldwide and the high prevalence of respiratory diseases is another major factor leading to the market growth. For Instance the stats published by the World Health Organization (WHO) on the number of people suffering from asthma and COPD were noted around 235 million worldwide. Lack of awareness about these diseases among people is leading to the growing number of incidences in turn driving the demand for smart inhalers.
The growth of smart inhalers market is also attributed to the increasing air pollution, and rising burden on healthcare services owing to the higher cases of asthma and COPD. Additionally, increasing adoption rate of smart inhalers for the proper management of these respiratory diseases are further boosting the growth of the market.

However, availability of substitutive products and high cost of the smart inhalers are expected to restrain the smart inhalers. On the other hand, untapped market in developing countries is expected to provide opportunity for the further market growth.

Segment Overview

Key components analysed in the smart inhalers market are Inhalers and nebulizers. Inhalers segment held the dominant share in 2018 and is expected to exhibit a sturdy growth rate in the future. On the other hand, the nebulizers segment is anticipated to exhibit growth owing to the introduction of technologically advanced solutions.

Hospital pharmacies are the largest end-use segment in share in 2018. Increasing advances in the healthcare industry due to rising R&D activities in the field of medical research is anticipated to fuel the demand for these smart devices in the coming years. Increasing incorporation of data management and personal medicine, particularly in research & hospital labs, because of its growing application scope, including patient engagement, patient health information tracking, workflow management, assurance at hospitals, labs, and other life science companies, is expected to propel the tech market growth.

Regional Overview

Geographically, the market has been segmented into four major economies including North America, Europe, Asia-Pacific, and LAMEA. North America consists of US, Canada, and Rest of North America. Europe comprises of the major countries including UK, Germany, France, Italy, Spain and Rest of Europe. Similarly, Asia Pacific consists of the major countries such as, Japan, China, India, South Korea, Australia and, Rest of Asia Pacific. LAMEA consists of Brazil, Saudi Arabia, UAE, and Rest of LAMEA.

North America region accounted for the major market share in 2018. The presence of established pharmaceutical companies and research labs coupled with higher awareness levels of diseases such as asthma and COPD amongst the end-users is expected to drive the demand. Furthermore, increasing R&D activities in the biotech & pharmaceutical industry and the existence of stringent regulatory compliance requirements is expected to fuel the growth of this vertical during the forecast period. Asia pacific is emerging as an outsourcing hub for the market due to its surging demand amongst the pharmaceutical manufacturers. Increasing cases of diseases such as asthma and other respiratory disorders are expected to fuel the market growth.

Competitor overview

Some of the key market participants include AstraZeneca, Cohero Health, Boehringer Ingelheim, Glaxo Smith Kline, Novartis International AG among various others. The top pharmaceutical companies are implementing digital technology for improved disease management and treatment such as that for asthma and COPD and also for improving the efficacy of various prescribed medicines. Extensive benefits ranging from considerably reducing hospital admissions to refining the efficacy of medicines, makes these smart inhalers the talk of the town in respiratory care segment.

Adherium, one of the key player in the market with majority of the product approvals to its name. as the smart inhalers is the lucrative market due to large number of customer base, acquisitions and collaborations between pharmaceutical companies, device manufacturers, and medical device companies are the major strategies to increase the market share. Moreover, the major players are also focused on the clinical trials and product approvals to stay competitive in the market. For instance; In January 2019; a Poland-based respiratory company FindAir launched the add-on accessory for its digital inhaler and started sales of their product to European consumers.

Key Players

  1. Adherium
  2. AstraZeneca
  3. Boehringer Ingelheim
  4. Cohero Health
  5. Glaxo Smith Kline
  6. Novartis International AG
  7. Opko Health
  8. ResMed, Inc.
  9. Teva Pharmaceutical Industries Limited
  10. Vectura Group plc.

Market Segmentation

By Product
  • Dry Powered Inhalers
  • Metered Dose Inhalers
  • Nebulizers
  • Others
By Indication
  • Asthma
  • COPD
By End Use
  • Hospitals
  • Online Pharmacies
  • Retail pharmacies
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Market Introduction 9

  • 1.1 Definition 9
  • 1.2 Scope of Study 9
  • 1.3 Research Objective 9
  • 1.4 Assumptions & Limitations 10
    • 1.4.1 Assumptions 10
    • 1.4.2 Limitations 10
  • 1.5 Market Structure 10

2 Research Methodology 11

  • 2.1 Research Process 11
  • 2.2 Primary Research 12
  • 2.3 Secondary Research 12

3 Market Dynamics 13

  • 3.1 Drivers 14
    • 3.1.1 Advantage over conventional inhalers 14
    • 3.1.2 Improve adherence 14
    • 3.1.3 Technological advancements worldwide 14
    • 3.1.4 Extensive use of smart computing devices 14
    • 3.1.5 Prevalence of respiratory disorders 15
  • 3.2 Restraints 15
    • 3.2.1 High price of Smart inhalers 15
    • 3.2.2 Limited availability of these products in some regions 15
    • 3.2.3 Data security concern related to security devices 15
    • 3.2.4 Regulating government policies 15
  • 3.3 Opportunities 16
    • 3.3.1 Expansion in developing countries 16
    • 3.3.2 Partnering with big pharmaceutical giants 16
    • 3.3.3 New product, innovative products 17

4 Market Factor Analysis 18

  • 4.1 Porter’s Five Forces Model 18
    • 4.1.1 Bargaining power of suppliers 19
    • 4.1.2 Bargaining Power of Buyers 19
    • 4.1.3 Threat of New Entrants 19
    • 4.1.4 Threat of Substitutes 19
    • 4.1.5 Intensity of Rivalry 19

5 Global Smart Inhalers Market, By Type 20

  • 5.1 Introduction 20

6 Global Smart Inhalers Market, By Application 24

  • 6.1 Introduction 24

7 Global Smart Inhalers Market, By End User 28

  • 7.1 Introduction 28

8 Global Smart Inhalers Market, By Region 32

  • 8.1 Introduction 32
  • 8.2 North America 33
  • 8.3 Europe 38
  • 8.4 Asia-Pacific 49
  • 8.5 Rest of World 58

9 Competitive Landscape 60

  • 9.1 Introduction 60

10 Company Profiles 62

  • 10.1 Adherium 62
    • 10.1.1 Company Overview 62
    • 10.1.2 Product/Business Segment Overview 62
    • 10.1.3 Adherium Health: Financials 62
    • 10.1.4 Key Development 63
    • 10.1.5 SWOT Analysis 64
  • 10.2 AstraZeneca 65
    • 10.2.1 Company Overview 65
    • 10.2.2 Product overview 65
    • 10.2.3 Financial Overview 66
    • 10.2.4 Key Development 67
    • 10.2.5 SWOT Analysis 68
  • 10.3 Cohero Health 69
    • 10.3.1 Company Overview 69
    • 10.3.2 Product Overview 69
    • 10.3.3 Cohero Health: Financials 69
    • 10.3.4 SWOT Analysis 70
  • 10.4 GlaxoSmithKline 71
    • 10.4.1 Company Overview 71
    • 10.4.2 Financial Overview 71
    • 10.4.3 Key Development 73
    • 10.4.4 SWOT Analysis 74
  • 10.5 Gecko Health Innovations, Inc 75
    • 10.5.1 Company Overview 75
    • 10.5.2 Gecko Health Innovations, Inc: Financials 75
    • 10.5.3 Key Development 76
    • 10.5.4 SWOT Analysis 76
  • 10.6 Inspiro Medical 77
    • 10.6.1 Company Overview 77
    • 10.6.2 Inspiro Medica: Financials 77
    • 10.6.3 Inspiro Medica: Key Developments 77
    • 10.6.4 SWOT Analysis 78
  • 10.7 Propeller Health 79
    • 10.7.1 Company Overview 79
    • 10.7.2 Product Overview 79
    • 10.7.3 Propeller Health: Financials 79
    • 10.7.4 Propeller Health: Key Developments 80

Report You Might be Interested